ERBB2 and neoplasm: In the subcutaneous ErbB2+ ovarian carcinoma SKOV3 xenograft model, ST8176AA1 at 15 or 30 mg/kg doses administered intraperitoneally (ip) four times every 4 days (q4dx4), starting 10 days after tumor transplantation, induced a statistically significant higher tumor growth inhibition compared to vehicle or trastuzumab (Figure 8A).